William Blair Reaffirms Outperform Rating for ARS Pharmaceuticals (NASDAQ:SPRY)

William Blair reissued their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY) in a report released on Friday,RTT News reports.

A number of other analysts also recently issued reports on the company. Leerink Partners raised their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Raymond James lifted their price target on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 14th. Finally, Oppenheimer started coverage on shares of ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Buy” and an average price target of $28.80.

ARS Pharmaceuticals Stock Down 4.6 %

SPRY stock opened at $11.24 on Friday. ARS Pharmaceuticals has a 52-week low of $7.50 and a 52-week high of $18.51. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -22.04 and a beta of 0.99. The business has a fifty day moving average of $12.02 and a two-hundred day moving average of $13.22.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 50,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the sale, the director now directly owns 210,346 shares in the company, valued at $2,334,840.60. This represents a 19.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Justin Chakma sold 25,000 shares of the business’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $14.39, for a total transaction of $359,750.00. Following the completion of the transaction, the insider now owns 136,380 shares of the company’s stock, valued at approximately $1,962,508.20. This trade represents a 15.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 617,102 shares of company stock worth $7,935,840 in the last three months. 40.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS purchased a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at about $73,000. BNP Paribas Financial Markets acquired a new stake in ARS Pharmaceuticals in the fourth quarter valued at approximately $75,000. Compass Capital Corp MA ADV purchased a new position in ARS Pharmaceuticals in the fourth quarter worth approximately $106,000. Ball & Co Wealth Management Inc. purchased a new position in ARS Pharmaceuticals in the fourth quarter worth approximately $105,000. Finally, Teacher Retirement System of Texas acquired a new position in ARS Pharmaceuticals during the 4th quarter worth approximately $122,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.